The benefits of AS make it an appealing option for selected patients with intermediate-risk disease.
No takes yet. Share an insight, caveat, or question.
Laurence Klotz (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: